macrolide therapy Search Results


macrolide therapy  (Nagai Nori USA INC)
90
Nagai Nori USA INC macrolide therapy
(Left) Dose-dependent effects of <t>macrolide</t> antibiotics on the release of NO from LPS-stimulated murine macrophages. The cells were incubated for 24 h with various concentrations of ERY (A) , RXT (B) , CLT (C) , and AZT (D) . Max doses (250 μM for ERY, RXT and AZT and 62.5 μM for CLT) were adjusted to achieve a cell viability ≥ 80%. Values on the vertical axe represent the percentage of control of NO formation in the culture medium after addition of LPS. (Right) Human in vitro liver microsome stabilities ( n = 3 per time point) for ERY (E) , RXT (F) , CLT (G) , and AZT (H) . Data are means ± STDEV; n = 6 for each concentration and time point.
Macrolide Therapy, supplied by Nagai Nori USA INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macrolide+therapy/macrolide+therapy/pmc05388737-245-8-26
Average 90 stars, based on 1 article reviews
macrolide therapy - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
4-week regimen of fluoroquinolone– macrolide combination therapy  (Blackwell Verlag)
90
Blackwell Verlag 4-week regimen of fluoroquinolone– macrolide combination therapy
(Left) Dose-dependent effects of <t>macrolide</t> antibiotics on the release of NO from LPS-stimulated murine macrophages. The cells were incubated for 24 h with various concentrations of ERY (A) , RXT (B) , CLT (C) , and AZT (D) . Max doses (250 μM for ERY, RXT and AZT and 62.5 μM for CLT) were adjusted to achieve a cell viability ≥ 80%. Values on the vertical axe represent the percentage of control of NO formation in the culture medium after addition of LPS. (Right) Human in vitro liver microsome stabilities ( n = 3 per time point) for ERY (E) , RXT (F) , CLT (G) , and AZT (H) . Data are means ± STDEV; n = 6 for each concentration and time point.
4 Week Regimen Of Fluoroquinolone– Macrolide Combination Therapy, supplied by Blackwell Verlag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macrolide+therapy/4+week+regimen+of+fluoroquinolone++macrolide+combination+therapy/pm21105887-70-18-3
Average 90 stars, based on 1 article reviews
4-week regimen of fluoroquinolone– macrolide combination therapy - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(Left) Dose-dependent effects of macrolide antibiotics on the release of NO from LPS-stimulated murine macrophages. The cells were incubated for 24 h with various concentrations of ERY (A) , RXT (B) , CLT (C) , and AZT (D) . Max doses (250 μM for ERY, RXT and AZT and 62.5 μM for CLT) were adjusted to achieve a cell viability ≥ 80%. Values on the vertical axe represent the percentage of control of NO formation in the culture medium after addition of LPS. (Right) Human in vitro liver microsome stabilities ( n = 3 per time point) for ERY (E) , RXT (F) , CLT (G) , and AZT (H) . Data are means ± STDEV; n = 6 for each concentration and time point.

Journal: Frontiers in Pharmacology

Article Title: Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production

doi: 10.3389/fphar.2017.00202

Figure Lengend Snippet: (Left) Dose-dependent effects of macrolide antibiotics on the release of NO from LPS-stimulated murine macrophages. The cells were incubated for 24 h with various concentrations of ERY (A) , RXT (B) , CLT (C) , and AZT (D) . Max doses (250 μM for ERY, RXT and AZT and 62.5 μM for CLT) were adjusted to achieve a cell viability ≥ 80%. Values on the vertical axe represent the percentage of control of NO formation in the culture medium after addition of LPS. (Right) Human in vitro liver microsome stabilities ( n = 3 per time point) for ERY (E) , RXT (F) , CLT (G) , and AZT (H) . Data are means ± STDEV; n = 6 for each concentration and time point.

Article Snippet: The characteristics of the clinical nonantimicrobial properties of macrolide therapy include effective doses that are much lower than the minimal inhibitory concentration (i.e., low-dose macrolide therapy) (Nagai et al., ; Fujii et al., ; Kudoh et al., ; Shitrit et al., ).

Techniques: Incubation, Control, In Vitro, Concentration Assay